Clinical Trial News and Research

RSS

ThromboGenics presents Phase IIa microplasmin intravitreal injection trial results at the ASRS conference

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative medicines for eye disease, vascular disease and cancer, today announces results of a Phase IIa trial evaluating microplasmin intravitreal injection for the treatment of Diabetic Macular Edema (MIVI II DME).

6 Oct 2009

Pico-Tesla commences Phase III clinical trial its Resonator system for treating Parkinson’s disease

Pico-Tesla, The Magneceutical™ Therapy Company, announced today that it has commenced a Phase III clinical trial of its patented Resonator™ system that facilitates the Company’s proprietary magnetic (Magneceutical™) therapy for treating Parkinson’s disease patients.

6 Oct 2009

Pomegranate juice beneficial for patients with elevated cardiovascular disease risk factors: Study

According to a clinical study released in The American Journal of Cardiology, a daily serving of POM Wonderful 100% Pomegranate Juice may decrease the progression of arterial plaque in patients with elevated cardiovascular disease risk factors. The study was intended to see if POM Wonderful 100% Pomegranate Juice may slow the progression of intima-media thickness of the carotid artery (CIMT) in patients with moderate coronary heart disease risk.

6 Oct 2009

Guided Therapeutics awarded $2.5M NCI grant for marketing LightTouch technology

Guided Therapeutics, Inc. today announced that it was awarded a $2.5 million matching grant by the National Cancer Institute (NCI) to bring to market and expand the array features for its LightTouch™ non-invasive cervical cancer detection technology. The award provides resources to complete the regulatory process and begin manufacturing ramp up for the device and single-patient-use disposable.

6 Oct 2009

Cumberland to present clinical trial data of Caldolor at the AAPM annual meeting

Cumberland Pharmaceuticals Inc. announced today that data from two key clinical trials for Caldolor®, an intravenous formulation of ibuprofen approved for treatment of pain and fever in adults, will be presented at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting to be held in Phoenix, Ariz., on October 8-11, 2009.

5 Oct 2009

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Seattle Genetics, Inc. announced today that it has discontinued the SeaGen MARINER clinical trial based on a determination that the trial would be unlikely to meet its primary endpoint of superior complete response rate in the dacetuzumab combination arm as compared to the placebo combination arm.

5 Oct 2009

ImThera Medical launches the aura6000 neurostimulation system for treating Obstructive Sleep Apnea

Today, at the American Academy of Otolaryngology-Head and Neck Surgery annual meeting, ImThera Medical, Inc. unveiled its new product, the aura6000™ neurostimulation system for the treatment of Obstructive Sleep Apnea (OSA).

5 Oct 2009

Positive results from Depomed's Phase 3 clinical trial of DM-1796 for postherpetic neuralgia

Depomed, Inc. today announced top-line results from a Phase 3 clinical trial demonstrating DM-1796 (also referred to as gabapentin ER) achieved a statistically significant reduction in pain associated with postherpetic neuralgia (PHN) versus placebo using the baseline observation carried forward (BOCF) method required by FDA.

5 Oct 2009

GSK reports positive Phase II results from trial evaluating GSK1838262 for post-herpetic neuralgia

GlaxoSmithKline and XenoPort, Inc. today announced top-line results from a Phase II clinical trial evaluating GSK1838262/XP13512 (gabapentin enacarbil) in adult patients with neuropathic pain associated with post-herpetic neuralgia (PHN) who have had a history of inadequate response to gabapentin doses of 1800 mg/day or higher.

5 Oct 2009

GVK Biosciences and Quantitative Solutions to develop and market clinical trial outcome databases

GVK Biosciences (GVK BIO), Asia’s leading integrated research services provider and Quantitative Solutions (QS), a modeling and simulation (M&S) consultancy to the pharmaceutical and biotech industry, announced a strategic partnership to develop and market clinical trial outcome databases.

5 Oct 2009

Phase I clinical trial results to test the safety and immunogenicity of VGX-3100 released

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.

5 Oct 2009

The Lewin Group issues recommendations to overcome barriers obstructing the lupus drug development

Today, The Lewin Group, a national health care consulting firm, issued recommendations on ways to overcome the barriers that have obstructed lupus drug development resulting in no new drug approval for this disease in more than 50 years - since the Eisenhower Administration.

From CSL Ltd 5 Oct 2009

Xcellerex and Itero collaborate in production of an undisclosed therapeutic protein

Xcellerex, Inc. and Itero Biopharmaceuticals, Inc. announced today that they have signed a Letter of Intent to enter into a strategic collaboration for the production of Itero’s lead product, an undisclosed commercially differentiated therapeutic protein. Itero will initiate technology transfer for the product to Xcellerex immediately.

3 Oct 2009

HCRI commences patient enrollment in dual antiplatelet therapy study

The Harvard Clinical Research Institute (HCRI) announced today that the first patients have been enrolled in the DAPT Study, marking the official initiation of the four-year clinical trial to investigate the duration of dual antiplatelet therapy (DAPT, the combination of aspirin and a thienopyridine/antiplatelet medication to reduce the risk of blood clots) following drug-eluting stent implantations.

3 Oct 2009

TMS Health expands its Boca Raton Headquarters

TMS Health, the largest provider of outbound and inbound Teleservices to the U.S. Pharmaceutical Industry, is expanding its Boca Raton headquarters.

3 Oct 2009

Cardium announces positive results from the Phase 1 / 2 clinical study of Excellarate

Cardium Therapeutics announced plans to report on preliminary safety and efficacy data from its Matrix Phase 2b Excellarate clinical study. Based on guidance from Cardium's independent clinical data management company which is currently completing the statistical analysis of all data for the Matrix clinical trial, Cardium expects to receive the locked unblinded data set and be in position to announce preliminary results on or before October 14, 2009.

3 Oct 2009

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

Quest PharmaTech Inc. ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has acquired a pipeline of late-stage immunotherapy product candidates from Paladin Labs Inc. ("Paladin").

3 Oct 2009

Chinese government places second purchase order for Sinovac Biotech's H1N1 vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that Sinovac has received its second purchase order for its H1N1 vaccine, PANFLU.1, from the Ministry of Industry and Information Technology of the People's Republic of China for the national stockpiling plan.

3 Oct 2009

Clinical study data of Thymosin beta 4 presented

REGENERX BIOPHARMACEUTICALS, INC. today reported on several clinical studies with Thymosin beta 4 (Tβ4) presented the Second International Symposium on Thymosins in Health and Disease, in Catania, Italy.

3 Oct 2009

FDA approves Bayer's IUD Mirena for treating heavy menstrual bleeding

The U.S. Food and Drug Administration today approved Mirena (levonorgestrel intrauterine system) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention. This is the first intrauterine device approved by the FDA for this additional indication.

3 Oct 2009

Clinical Trial News and Research

ThromboGenics presents Phase IIa microplasmin intravitreal injection trial results at the ASRS conference

Pico-Tesla commences Phase III clinical trial its Resonator system for treating Parkinson’s disease

Pomegranate juice beneficial for patients with elevated cardiovascular disease risk factors: Study

Guided Therapeutics awarded $2.5M NCI grant for marketing LightTouch technology

Cumberland to present clinical trial data of Caldolor at the AAPM annual meeting

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

ImThera Medical launches the aura6000 neurostimulation system for treating Obstructive Sleep Apnea

Positive results from Depomed's Phase 3 clinical trial of DM-1796 for postherpetic neuralgia

GSK reports positive Phase II results from trial evaluating GSK1838262 for post-herpetic neuralgia

GVK Biosciences and Quantitative Solutions to develop and market clinical trial outcome databases

Phase I clinical trial results to test the safety and immunogenicity of VGX-3100 released

The Lewin Group issues recommendations to overcome barriers obstructing the lupus drug development

Xcellerex and Itero collaborate in production of an undisclosed therapeutic protein

HCRI commences patient enrollment in dual antiplatelet therapy study

TMS Health expands its Boca Raton Headquarters

Cardium announces positive results from the Phase 1 / 2 clinical study of Excellarate

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

Chinese government places second purchase order for Sinovac Biotech's H1N1 vaccine

Clinical study data of Thymosin beta 4 presented

FDA approves Bayer's IUD Mirena for treating heavy menstrual bleeding

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer